Abbott Choose AbbVie as the new name for the future company based in pharmaceutical research.
the company continues its March towards separation, at the end of 2012, two companies of the health care that publicly traded.
Madrid, April 2012.- Abbott has announced, Wednesday 21 of March, to AbbVie (pronounced Ab saw) will be the name of the new independent company based in pharmaceutical research that hopes to release by the end of 2012.
Give a name to the new company is the most recent milestone of the process that began in October of 2011 when Abbott announced that it would separate into two companies that cotizarÃan in bag; diversified medical products and pharmaceutical research-based. AbbVie, the company based in pharmaceutical research, will include the current portfolio of Abbott of Biologicals and pharmaceuticals leading patent. The company’s diversified medical products, which will retain on behalf of Abbott, will be composed of the current portfolio of Abbott medical products diversified, including business of generic pharmaceutical products of brand, devices, Diagnostics and nutrition. both companies are global leaders in their respective industries.
Miles D. White will remain President and CEO of Abbott. Richard a. Gonzalez, currently Executive Vice President of pharmaceutical products, will become President and CEO of AbbVie.
The name has its origins in a combination of Abbott and vie ”, in reference to the Latin root saw ” which means life.
The beginning of the name connects to the new company with Abbott and his heritage of being pioneers in science, ” said Mr. Gonzalez. ‘ Vie ’ underlines the vital work that the company will continue to be carried out to improve the lives of people in all the world. ”
with a pioneer product family and an approach based on innovation and the development of new formulas covering the different medical needs, AbbVie will focus on the continuous improvement of the health of the patients ” said Mr White.
Based on the research-based pharmaceutical company currently has revenues of almost $18 billion and will possess a sustainable portfolio of leading brands in the market, which include Procrin, Synagis, Humira and Kaletra among others. In addition, a product portfolio in developing attractive with regard to innovative r & d assets – in specialized therapeutic areas important as Hepatitis C, immunology, chronic kidney disease, women’s health, oncology and neuroscience – will enable future growth.
The graphic identity and logo AbbVie will be presented when the new company is launched.
About Abbott
Abbott is a biomedical company that is dedicated to the research, development, manufacture and marketing of pharmaceuticals, nutritional, health and diagnosis. The company employs approximately 91,000 people worldwide and sells its products in more than 130 countries.
Abbott is certified as the best company to work in the health sector and the second in the general ranking of sectors according to Best 2009″ Spain 2010. Abbott has over 1,500 employees and 61 years of history in our country. The company’s activity is oriented to meet the needs of patients with chronic diseases and high-impact clinical, economic, social, and emotional. Abbott has presence in all areas of the Spanish healthcare industry (including r & d and manufacturing at its centres in Madrid, Granada and Alcobendas). Its products cover all phases of the process of the disease (prevention, diagnosis, treatment and healing) and are present at every moment of the life cycle: newborn, childhood, adolescence, maturity and old age.
